We are live on ! Find out more
MRNS

Marinus Pharmaceuticals, Inc
MRNS

Delisted

MRNS was delisted on the 10th of February, 2025.

Back to rankings

106 hedge funds and large institutions have $485M invested in Marinus Pharmaceuticals, Inc in 2023 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 23 increasing their positions, 28 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

457% more call options, than puts

Call options by funds: $11.1M | Put options by funds: $1.99M

91% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 22

71% more capital invested

Capital invested by funds: $284M → $485M (+$201M)

23% more funds holding

Funds holding: 86 → 106 (+20)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

18% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 28

Holders
106
Holders Change
+20
Holders Change %
+23.26%
% of All Funds
1.66%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
42
Increased
23
Reduced
28
Closed
22
Calls
$11.1M
Puts
$1.99M
Net Calls
+$9.09M
Net Calls Change
+$1.21M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$23.7M
2
Jennison Associates
Jennison Associates
New York
+$16M
3
State Street
State Street
Massachusetts
+$6.4M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$5.97M
5
IC
Ikarian Capital
Texas
+$5.24M

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$15.7M
2
ACM
AIGH Capital Management
Maryland
-$9.22M
3
Millennium Management
Millennium Management
New York
-$7.86M
4
WP
Woodline Partners
California
-$6.83M
5
SCM
Suvretta Capital Management
New York
-$6.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
ABG
26
Ally Bridge Group
New York
$4.24M +$3.34M +390,418 New
Walleye Capital
27
Walleye Capital
New York
$3.91M +$2.82M +329,362 +1,066%
D.E. Shaw & Co
28
D.E. Shaw & Co
New York
$3.85M +$2.28M +266,521 +302%
Citadel Advisors
29
Citadel Advisors
Florida
$3.28M +$1.02M +118,904 +65%
Prudential Financial
30
Prudential Financial
New Jersey
$2.95M +$2.32M +271,280 New
JFG
31
Jefferies Financial Group
New York
$2.76M -$2.14M -249,772 -50%
Two Sigma Investments
32
Two Sigma Investments
New York
$2.42M +$1.91M +222,484 New
Bank of Montreal
33
Bank of Montreal
Ontario, Canada
$2.06M -$1.4M -163,106 -46%
PHP
34
Parkman Healthcare Partners
Connecticut
$1.86M -$676K -78,925 -32%
EI
35
EAM Investors
California
$1.86M – – –
Bank of New York Mellon
36
Bank of New York Mellon
New York
$1.78M +$957K +111,757 +215%
Jane Street
37
Jane Street
New York
$1.72M -$1.25M -145,400 -48%
Wellington Management Group
38
Wellington Management Group
Massachusetts
$1.7M +$1.34M +156,978 New
SAM
39
Simplify Asset Management
Nevada
$1.63M – – –
SSA
40
Schonfeld Strategic Advisors
New York
$1.62M +$867K +101,227 +210%
N
41
Nuveen
North Carolina
$1.51M +$1.19M +139,477 New
Charles Schwab
42
Charles Schwab
California
$1.47M +$989K +115,496 +590%
CSS
43
Cubist Systematic Strategies
Connecticut
$1.33M +$1.05M +122,190 +174,557%
Morgan Stanley
44
Morgan Stanley
New York
$1.07M -$198K -23,146 -19%
Simplex Trading
45
Simplex Trading
Illinois
$996K -$164K -19,182 -17%
IBT
46
International Biotechnology Trust
United Kingdom
$977K +$771K +90,000 New
Federated Hermes
47
Federated Hermes
Pennsylvania
$890K +$702K +81,964 New
MCM
48
Moore Capital Management
New York
$815K +$642K +75,000 New
Two Sigma Advisers
49
Two Sigma Advisers
New York
$804K +$634K +74,025 New
RhumbLine Advisers
50
RhumbLine Advisers
Massachusetts
$727K +$573K +66,902 New
1
2
3 4 5

MRNS Hedge Fund Activity: Q2 2023 in Review

106 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q2 2023, worth a combined $485M — up 71% from $284M a quarter earlier.

Buyers outnumbered sellers: 42 funds opened new MRNS positions and 22 closed out — a net gain of 20 holders — while 23 added to existing stakes and 28 trimmed.

The largest buyer was BlackRock, adding an estimated $23.7M. The largest seller was Point72 Asset Management, cutting an estimated $15.7M.

  • 106 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q2 2023, up from 86 in Q1 2023.
  • Funds reported $485M of Marinus Pharmaceuticals, Inc stock for Q2 2023, up 71% quarter-over-quarter.
  • 42 funds opened new Marinus Pharmaceuticals, Inc positions in Q2 2023 and 22 closed out, a net change of +20 holders.
  • The largest Marinus Pharmaceuticals, Inc buyer in Q2 2023 was BlackRock, an estimated $23.7M added.
  • The largest Marinus Pharmaceuticals, Inc seller in Q2 2023 was Point72 Asset Management, an estimated $15.7M sold.

Based on aggregated 13F filings for Q2 2023.